Reinterventions after F/B-EVAR were necessary in 26% of patients, most commonly for type III endoleaks and target artery complications. Whereas all but one reintervention was successful, many of these required complex procedures with significant morbidity and mortality. Development of strategies to eliminate type III endoleaks by improving component junction integrity and to ensure target artery primary patency are key next steps in the evolution of F/B-EVAR.

No abstract

No abstract

No abstract

compared between the two groups. Long-term follow-up was collected by telephone survey inquiring about intensity of symptoms on a numeric rating scale of 0 to 10 before and after treatment. A multivariable analysis was performed to identify predictors of recurrence.Results: There were 362 patients with 529 veins treated. The mean age was 59.2 6 14.4 years (63% women). There were significant differences in history of hypertension (P ¼ .02) and deep venous thrombosis (P ¼ .02) between the two groups (Table I). The clinical success, technical success, and complication rates were 80%, 95.6%, and 11.5%. There were no significant differences between the two groups in outcomes (Table II). After a mean follow-up of 27.5 months, recurrence rate was 22.2%. There was a trend toward higher recurrence in group B that did not reach statistical significance (P ¼ .1). On multivariable analysis, there was no clinical or technical factor that could predict recurrence.Conclusions: The experience with radiofrequency VA does not support difference in outcomes when treatment starts at $3 cm from the deep junction. However, there is a trend toward increased longterm recurrence that warrants further investigation with the newer technology.